FDA will hold a public workshop on prostate cancer as part of its ongoing series of meetings on oncology clinical trial endpoints.
Trial to investigate efficacy of aloe vera in patients with interstitial cystitis
"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
AUGS Position Statement on Gender Affirmation
The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
UroActive System shows promise in first female patient with SUI
Overall, the patient met the study’s primary outcome measures of successful device activation and the rate of explants and revisions at 6 months.
Initial results published for 177Lu-rhPSMA-10.1 in mCRPC
All patients treated with 177Lu-rhPSMA-10.1 had reductions in their PSA levels from the start of treatment and none experienced a serious treatment-related adverse event.
2 Commerce Drive Cranbury, NJ 08512